skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

International journal of infectious diseases, 2020-05, Vol.94, p.91-95 [Peer Reviewed Journal]

2020 The Authors ;Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved. ;2020 The Authors 2020 ;ISSN: 1201-9712 ;EISSN: 1878-3511 ;DOI: 10.1016/j.ijid.2020.03.017 ;PMID: 32173574

Full text available

Citations Cited by
  • Title:
    Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis
  • Author: Yang, Jing ; Zheng, Ya ; Gou, Xi ; Pu, Ke ; Chen, Zhaofeng ; Guo, Qinghong ; Ji, Rui ; Wang, Haojia ; Wang, Yuping ; Zhou, Yongning
  • Subjects: Betacoronavirus ; Clinical characteristics ; Comorbidities ; Comorbidity ; Coronavirus Infections - epidemiology ; Cough ; COVID-19 ; Epidemiology ; Fever - etiology ; Humans ; Meta-analysis ; Pandemics ; Pneumonia, Viral - epidemiology ; Prevalence ; Risk Factors ; SARS-CoV-2
  • Is Part Of: International journal of infectious diseases, 2020-05, Vol.94, p.91-95
  • Description: •COVID -19 cases are now confirmed in multiple countries.•Assessed the prevalence of comorbidities in infected patients.•Comorbidities are risk factors for severe compared with non-severe patients.•Help the health sector guide vulnerable populations and assess the risk of deterioration. An outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China; the epidemic is more widespread than initially estimated, with cases now confirmed in multiple countries. The aim of this meta-analysis was to assess the prevalence of comorbidities in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients and the risk of underlying diseases in severe patients compared to non-severe patients. A literature search was conducted using the databases PubMed, EMBASE, and Web of Science through February 25, 2020. Odds ratios (ORs) and 95% confidence intervals (CIs) were pooled using random-effects models. Seven studies were included in the meta-analysis, including 1 576 infected patients. The results showed the most prevalent clinical symptom was fever (91.3%, 95% CI: 86–97%), followed by cough (67.7%, 95% CI: 59–76%), fatigue (51.0%, 95% CI: 34–68%) and dyspnea (30.4%, 95% CI: 21–40%). The most prevalent comorbidities were hypertension (21.1%, 95% CI: 13.0–27.2%) and diabetes (9.7%, 95% CI: 7.2–12.2%), followed by cardiovascular disease (8.4%, 95% CI: 3.8–13.8%) and respiratory system disease (1.5%, 95% CI: 0.9–2.1%). When compared between severe and non-severe patients, the pooled OR of hypertension, respiratory system disease, and cardiovascular disease were 2.36 (95% CI: 1.46–3.83), 2.46 (95% CI: 1.76–3.44) and 3.42 (95% CI: 1.88–6.22) respectively. We assessed the prevalence of comorbidities in the COVID-19 patients and found that underlying disease, including hypertension, respiratory system disease and cardiovascular disease, may be risk factors for severe patients compared with non-severe patients.
  • Publisher: Canada: Elsevier Ltd
  • Language: English
  • Identifier: ISSN: 1201-9712
    EISSN: 1878-3511
    DOI: 10.1016/j.ijid.2020.03.017
    PMID: 32173574
  • Source: GFMER Free Medical Journals
    MEDLINE
    DOAJ Directory of Open Access Journals
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait